The Otolic* system is based on years of learning, research and development. Vestibular implant technology is opening a new window to the brain.
Physicians may use the system to treat previously untreated vestibular pathologies. Also a new exciting era start for the treatment of motor disorders as Parkinson. Follow us on LinkedIn, which is the primary place where you can connect with us, join the discussion and stay up to date with our progress.
The first clinical trial in humans with chronic electrical stimulation of the otolith organ in patients with bilateral vestibular dysfunction and deafness was carried out by the European Consortium under the auspices of the European Commission (BionicVest), using the first device for cochlear and otolith stimulations designed by Las Palmas University Engineer Dept.
*For investigational use only.
There is not a vestibular restoration treatment.
The different treatment options for vestibular disorders currently available on the vestibular market are considered symptomatic, as they can help reduce the symptoms of a vestibular disorder, but they cannot restore the vestibular function. The four main therapies currently available are:
In severe cases, these treatments are not effective enough thus the patient remains without useful treatment.
Ground-breaking results were obtained in the first clinical trial in humans. This was a first and essential validation step that laid the foundation for this new treatment.
Over the past 3 years, the first human clinical study of vestibular otolith implant technology has demonstrated the benefit of this technology for the treatment of bilateral vestibular disorders.
The Otolic implant obtained spectacular results and showed that the successful restoration of vestibular function through electrical stimulation of the otolith organ could become a clinical reality. Where there was no solution for these people before, balance improvement and even restoration is feasible.
The vestibular system provides the most information for motor control.
Dopaminergic activity in the basal ganglia has increased by 30% with the vestibular implant active. The side contralateral to the vestibular implant has improved:
the improvement on the ipsilateral side are:
The future opens up to new therapeutic avenues for the treatment of Parkinson's symptoms and Parkinsonisms.